Trials / Terminated
TerminatedNCT04601857
Futibatinib and Pembrolizumab Combination in the Treatment of Advanced or Metastatic Urothelial Carcinoma
A Phase 2 Study Evaluating Futibatinib (TAS 120) Plus Pembrolizumab in the Treatment of Advanced or Metastatic Urothelial Carcinoma
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 43 (actual)
- Sponsor
- Taiho Oncology, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of the trial is to evaluate the antitumor activity and confirm the safety for the combination of Fibroblast Growth Factor Receptor (FGFR) inhibitor futibatinib and anti-programmed cell death-1 (PD-1) antibody pembrolizumab in patients with advanced or metastatic urothelial cancer who are not candidates to receive a platinum-based treatment regimens.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Futibatinib | Oral |
| DRUG | Pembrolizumab | IV |
Timeline
- Start date
- 2021-01-07
- Primary completion
- 2024-03-08
- Completion
- 2025-09-16
- First posted
- 2020-10-26
- Last updated
- 2025-12-31
- Results posted
- 2025-12-31
Locations
18 sites across 3 countries: United States, France, Spain
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04601857. Inclusion in this directory is not an endorsement.